Skip to main content
Article thumbnail
Location of Repository

Ovarian VEGF165b expression regulates follicular development, corpus luteum function and fertility

By Y Qiu, M Seager, A Osman, J Castle-Miller, H Bevan, D J Tortonese, D Murphy, S J Harper, H M Fraser, L F Donaldson and D O Bates

Abstract

Angiogenesis and vascular regression are critical for the female ovulatory cycle. They enable progression and regression of follicular development, and corpora lutea formation and regression. Angiogenesis in the ovary occurs under the control of the vascular endothelial growth factor-A (VEGFA) family of proteins, which are generated as both pro-(VEGF165) and anti(VEGF165b)-angiogenic isoforms by alternative splicing. To determine the role of the VEGF165b isoforms in the ovulatory cycle, we measured VEGF165b expression in marmoset ovaries by immunohistochemistry and ELISA, and used transgenic mice over-expressing VEGF165b in the ovary. VEGF165b was expressed in the marmoset ovaries in granulosa cells and theca, and the balance of VEGF165b:VEGF165 was regulated during luteogenesis. Mice over-expressing VEGF165b in the ovary were less fertile than wild-type littermates, had reduced secondary and tertiary follicles after mating, increased atretic follicles, fewer corpora lutea and generated fewer embryos in the oviduct after mating, and these were more likely not to retain the corona radiata. These results indicate that the balance of VEGFA isoforms controls follicle progression and luteogenesis, and that control of isoform expression may regulate fertility in mammals, including in primates

Topics: Research
Publisher: BioScientifica
OAI identifier: oai:pubmedcentral.nih.gov:3325318
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2008). A novel molecular mechanism for anticancer drug-induced ovarian failure: Irinotecan HCl, an anticancer topoisomerase I inhibitor, induces specific FasL expression in granulosa cells of large ovarian follicles to enhance follicular apoptosis.
    2. (2006). A VEGF-A splice variant defective for heparan sulfate and neuropilin-1 binding shows attenuated signaling through VEGFR-2. Cellular and Molecular Life Sciences 63 2067–2077. (doi:10.1007/s00018-006-6254-9) Charnock-Jones
    3. (1998). Alternative splicing offollicle-stimulating hormone receptor pre-mRNA: cloning and characterization of twoalternatively spliced mRNA transcripts.
    4. (2004). Anti-angiogenic treatment of endometriosis: biochemical aspects.
    5. (1998). Developmental and hormonal regulation of keratinocyte growth factor expression and action in the ovarian follicle. Endocrinology 139 228–235. (doi:10.1210/en.139.1.228) Pedersen T & Peters H
    6. (2004). Image processing with ImageJ.
    7. (2009). Neutralization of vascular endothelial growth factor antiangiogenic isoforms is more effective than treatment with proangiogenic isoforms in stimulating vascular development and follicle progression in the perinatal rat ovary.
    8. (1993). Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis.
    9. (2006). The endogenous anti-angiogenic family of splice variants of VEGF, VEGFxxxb, are down-regulated in pre-eclamptic placentae at term.
    10. (2008). VEGF 165 b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy.
    11. (2006). VEGF165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.